These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7540426)

  • 1. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.
    Möller HJ; Müller H; Borison RL; Schooler NR; Chouinard G
    Eur Arch Psychiatry Clin Neurosci; 1995; 245(1):45-9. PubMed ID: 7540426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
    Cesková E; Svestka J
    Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone: clinical development: north American results.
    Marder SR
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():92A-93A. PubMed ID: 1379883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The negative component in schizophrenia.
    Möller HJ
    Acta Psychiatr Scand Suppl; 1995; 388():11-4. PubMed ID: 7541597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desmopressin for risperidone-induced enuresis.
    Bennett JA; Keck PE; Wallhausser LJ
    Ann Clin Psychiatry; 1994 Jun; 6(2):139-40. PubMed ID: 7528602
    [No Abstract]   [Full Text] [Related]  

  • 6. Risperidone: clinical safety and efficacy in schizophrenia.
    Borison RL; Pathiraja AP; Diamond BI; Meibach RC
    Psychopharmacol Bull; 1992; 28(2):213-8. PubMed ID: 1381102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients.
    Wilms G; Van Ongeval C; Baert AL; Claus A; Bollen J; De Cuyper H; Eneman M; Malfroid M; Peuskens J; Heylen S
    Acta Psychiatr Scand; 1992 Apr; 85(4):306-12. PubMed ID: 1375802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone in the treatment of schizophrenia.
    Marder SR; Meibach RC
    Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial.
    Min SK; Rhee CS; Kim CE; Kang DY
    Yonsei Med J; 1993 Jun; 34(2):179-90. PubMed ID: 7691017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
    Peuskens J
    Br J Psychiatry; 1995 Jun; 166(6):712-26; discussion 727-33. PubMed ID: 7545060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group.
    Müller-Spahn F
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():90A-91A. PubMed ID: 1379882
    [No Abstract]   [Full Text] [Related]  

  • 13. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.
    Claus A; Bollen J; De Cuyper H; Eneman M; Malfroid M; Peuskens J; Heylen S
    Acta Psychiatr Scand; 1992 Apr; 85(4):295-305. PubMed ID: 1375801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol.
    Lindström E; von Knorring L
    Pharmacopsychiatry; 1994 May; 27(3):108-13. PubMed ID: 7521534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
    Marder SR; Davis JM; Chouinard G
    J Clin Psychiatry; 1997 Dec; 58(12):538-46. PubMed ID: 9448657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of risperidone on positive features of schizophrenia.
    McEvoy JP
    J Clin Psychiatry; 1994 May; 55 Suppl():18-21. PubMed ID: 7520904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical review of risperidone.
    Chouinard G; Arnott W
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S89-95. PubMed ID: 7504574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.